MX2017016103A - Factor estimulador de colonia de granulocito (gcsf) pegilado. - Google Patents

Factor estimulador de colonia de granulocito (gcsf) pegilado.

Info

Publication number
MX2017016103A
MX2017016103A MX2017016103A MX2017016103A MX2017016103A MX 2017016103 A MX2017016103 A MX 2017016103A MX 2017016103 A MX2017016103 A MX 2017016103A MX 2017016103 A MX2017016103 A MX 2017016103A MX 2017016103 A MX2017016103 A MX 2017016103A
Authority
MX
Mexico
Prior art keywords
gcsf
stimulating factor
colony stimulating
granulocyte colony
pegylated granulocyte
Prior art date
Application number
MX2017016103A
Other languages
English (en)
Inventor
Abuchowski Abraham
G Jubin Ronald
J Buontempo Peter
KAZO Friedericke
Original Assignee
Ambio Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambio Pharmaceuticals Llc filed Critical Ambio Pharmaceuticals Llc
Publication of MX2017016103A publication Critical patent/MX2017016103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta invención se refiere a conjugados novedosos de PEGx-GCSF, en el cual x es la cantidad de PEG por GCSF y varía de 4 a 8. La invención también se refiere a poblaciones de PEG[x]-GCSF de conjugados de PEGx-GCSF individuales, en las cuales [x] es la cantidad promedio de PEG por GCSF de la población y es de 4 o mayor. Las composiciones de la invención tienen eficacia terapéutica inesperada, al tiempo que evitan o reducen sustancialmente la probabilidad de efectos secundarios adversos.
MX2017016103A 2015-06-11 2016-06-13 Factor estimulador de colonia de granulocito (gcsf) pegilado. MX2017016103A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562174373P 2015-06-11 2015-06-11
US201562184042P 2015-06-24 2015-06-24
PCT/US2016/037278 WO2016201448A2 (en) 2015-06-11 2016-06-13 Pegylated granulocyte colony stimulating factor (gcsf)

Publications (1)

Publication Number Publication Date
MX2017016103A true MX2017016103A (es) 2018-05-22

Family

ID=57504855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016103A MX2017016103A (es) 2015-06-11 2016-06-13 Factor estimulador de colonia de granulocito (gcsf) pegilado.

Country Status (11)

Country Link
US (1) US20160361426A1 (es)
EP (1) EP3307757A4 (es)
JP (1) JP2018519359A (es)
KR (1) KR20180017104A (es)
CN (1) CN107949565A (es)
AU (1) AU2016277147A1 (es)
CA (1) CA2988988A1 (es)
IL (1) IL256167A (es)
MX (1) MX2017016103A (es)
RU (1) RU2018100425A (es)
WO (1) WO2016201448A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121448A2 (en) * 2020-03-20 2023-01-25 Amgen Inc. Determination of free n-terminus of pegfilgrastim using an acid protease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP1425304B9 (en) * 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
CN1646138B (zh) * 2002-03-25 2010-05-26 碧欧塞根公司 对g2a受体特异性的激动剂配体的制药用途
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4657219B2 (ja) * 2003-12-03 2011-03-23 バイオジェネリックス アーゲー ＧｌｙｃｏＰＥＧ化された顆粒球コロニー刺激因子
BRPI0611221A2 (pt) * 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
US20070092482A1 (en) * 2005-08-04 2007-04-26 Bossard Mary J Conjugates of a G-CSF moiety and a polymer
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
CN101602801A (zh) * 2008-06-13 2009-12-16 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体
WO2011041376A1 (en) * 2009-09-30 2011-04-07 Prolong Pharmaceuticals Modified granulocyte colony stimulating factor (g-csf)
WO2011075606A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CN104109235B (zh) * 2014-05-30 2017-07-18 厦门赛诺邦格生物科技股份有限公司 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质

Also Published As

Publication number Publication date
WO2016201448A3 (en) 2017-02-09
RU2018100425A3 (es) 2019-11-21
RU2018100425A (ru) 2019-07-15
AU2016277147A1 (en) 2018-01-18
EP3307757A4 (en) 2019-03-13
WO2016201448A2 (en) 2016-12-15
US20160361426A1 (en) 2016-12-15
IL256167A (en) 2018-04-30
CN107949565A (zh) 2018-04-20
EP3307757A2 (en) 2018-04-18
JP2018519359A (ja) 2018-07-19
CA2988988A1 (en) 2016-12-15
KR20180017104A (ko) 2018-02-20

Similar Documents

Publication Publication Date Title
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
EP3173092A3 (en) Rna containing composition for treatment of tumor diseases
MX2018000351A (es) Composición para el cuidado de telas que comprende poliolésteres insaturados metatesizados.
EP4234551A3 (en) Pyridazinones as parp7 inhibitors
MA46245A (fr) Dinucléotides cycliques comme agonistes (stimulateur des gènes de l'interféron)
PH12018500719A1 (en) Oligonucleotide compositions and methods thereof
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
MX2022001292A (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
EP4310500A3 (en) Methods and compositons for the activation of gamma-delta t-cells
WO2018098117A8 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
MX2011010449A (es) Derivados de oxadiazol.
EP4299133A3 (en) Compositions and methods for the delivery of therapeutics
PH12019501193A1 (en) Use of chelating agents for improving color stability of resorcinol
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
EP4218736A3 (en) Compositions comprising 15-hepe
MX2020001885A (es) Formulaciones de daptomicina.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
IL290535A (en) Preparations, formulations, production and purification of interleukin
MX2019001907A (es) Composicion para el cuidado de telas que comprende copolimeros de glicerido.
MX2021006488A (es) Composiciones para mejorar la funcion sexual.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2022003398A (es) Composicion micelar inmunoestimulante.